The Alliance for Healthier Communities represents community-governed healthcare organizations in Ontario, Canada including Community Health Centres, which provide primary care to more disadvantaged populations.
A learning health system model can be used to efficiently evaluate and incorporate evidence-based care into practice. However, there is a paucity of evidence describing key organizational attributes needed to ensure a successful learning health system within primary care. We interviewed stakeholders for a primary care learning health system in Ontario, Canada (the Alliance for Healthier Communities) to identify strengths and areas for improvement.
Supervised consumption services (SCS), intended to reduce morbidity and mortality among people who inject drugs, have been implemented in a variety of delivery models. We describe and compare access to and uptake of co-located and external services among clients accessing harm reduction-embedded (HR-embedded) and community health center-embedded (CHC-embedded) SCS models.
Considering the novelty of the area of a 2-year study on impact of family loss and separation on refugee youth in Toronto, the research team decided to conduct a scoping review of the existing literature as a foundation document that included the extent, range, geography, and nature of research on the topic of interest.
Note: Supplementary materials for this paper, including references and French-language translation are available on the Lancet's website.
Summary
This "viewpoint" (opinion) article was published onlne at jamanetwork.com
The research team surveyed primary care leaders across Ontario using validated survey instruments and looked at the below factors, and we found that the Processes directly and positively impacted Outcomes, and the Structures indirectly and favorably impacted Outcomes through - or as mediated by - their direct impact on Processes.
In the United States, mifepristone is available for medical abortion (for use with misoprostol) only with Risk Evaluation and Mitigation Strategy (REMS) restrictions, despite an absence of evidence to support such restrictions. Mifepristone has been available in Canada with a normal prescription since November 2017.
